Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Reuters

06/30

Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2547096241"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547096241\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547096241?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547096241","market":"nz","top_or_hot":-1,"title":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nNDL5JT1nv:1","article_id":"2547096241","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547096241","pubTimestamp":1751284545,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications. Cuprina Holdings  Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results beco","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4198":"医疗保健用品","CUPR":"Cuprina Holdings (Cayman) Limited"},"translate_title":"Cuprina Holdings宣布牛蛙胶原蛋白肽用于高级伤口护理和药妆应用的新临床研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CUPR":0.9},"content_text":"Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications\n    \n\n        Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}